These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 7923198)

  • 61. Insulin-like growth factor I reduces ubiquitin and ubiquitin-conjugating enzyme gene expression but does not inhibit muscle proteolysis in septic rats.
    Fang CH; Li BG; Sun X; Hasselgren PO
    Endocrinology; 2000 Aug; 141(8):2743-51. PubMed ID: 10919258
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Adrenodemedullation activates the Ca
    Manfredi LH; Lustrino D; Machado J; Silveira WA; Zanon NM; Navegantes LC; Kettelhut IC
    J Appl Physiol (1985); 2017 Feb; 122(2):317-326. PubMed ID: 27765842
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effects of ornithine alpha-ketoglutarate on protein metabolism in Yoshida sarcoma-bearing rats.
    Segaud F; Combaret L; Neveux N; Attaix D; Cynober L; Moinard C
    Clin Nutr; 2007 Oct; 26(5):624-30. PubMed ID: 17590483
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Increased mRNA levels for components of the lysosomal, Ca2+-activated, and ATP-ubiquitin-dependent proteolytic pathways in skeletal muscle from head trauma patients.
    Mansoor O; Beaufrere B; Boirie Y; Ralliere C; Taillandier D; Aurousseau E; Schoeffler P; Arnal M; Attaix D
    Proc Natl Acad Sci U S A; 1996 Apr; 93(7):2714-8. PubMed ID: 8610106
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Evaluation of signals activating ubiquitin-proteasome proteolysis in a model of muscle wasting.
    Mitch WE; Bailey JL; Wang X; Jurkovitz C; Newby D; Price SR
    Am J Physiol; 1999 May; 276(5):C1132-8. PubMed ID: 10329962
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Metabolic mechanisms of different types of disuse muscular atrophy].
    Goncharova LA; Kazarian VA; Shipilova TIu; Rapoport EA
    Vopr Med Khim; 1982; 28(4):105-9. PubMed ID: 6180553
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Regulation of ATP-ubiquitin-dependent proteolysis in muscle wasting.
    Attaix D; Taillandier D; Temparis S; Larbaud D; Aurousseau E; Combaret L; Voisin L
    Reprod Nutr Dev; 1994; 34(6):583-97. PubMed ID: 7840873
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Identification of cathepsin L as a differentially expressed message associated with skeletal muscle wasting.
    Deval C; Mordier S; Obled C; Bechet D; Combaret L; Attaix D; Ferrara M
    Biochem J; 2001 Nov; 360(Pt 1):143-50. PubMed ID: 11696001
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Anticytokine treatment prevents the increase in the activity of ATP-ubiquitin- and Ca(2+)-dependent proteolytic systems in the muscle of tumour-bearing rats.
    Costelli P; Bossola M; Muscaritoli M; Grieco G; Bonelli G; Bellantone R; Doglietto GB; Baccino FM; Rossi Fanelli F
    Cytokine; 2002 Jul; 19(1):1-5. PubMed ID: 12200106
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Resveratrol does not ameliorate muscle wasting in different types of cancer cachexia models.
    Busquets S; Fuster G; Ametller E; Olivan M; Figueras M; Costelli P; Carbó N; Argilés JM; López-Soriano FJ
    Clin Nutr; 2007 Apr; 26(2):239-44. PubMed ID: 17261345
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Catecholamines inhibit Ca(2+)-dependent proteolysis in rat skeletal muscle through beta(2)-adrenoceptors and cAMP.
    Navegantes LC; Resano NM; Migliorini RH; Kettelhut IC
    Am J Physiol Endocrinol Metab; 2001 Sep; 281(3):E449-54. PubMed ID: 11500299
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Rates of ubiquitin conjugation increase when muscles atrophy, largely through activation of the N-end rule pathway.
    Solomon V; Baracos V; Sarraf P; Goldberg AL
    Proc Natl Acad Sci U S A; 1998 Oct; 95(21):12602-7. PubMed ID: 9770532
    [TBL] [Abstract][Full Text] [Related]  

  • 73. USP19 is a ubiquitin-specific protease regulated in rat skeletal muscle during catabolic states.
    Combaret L; Adegoke OA; Bedard N; Baracos V; Attaix D; Wing SS
    Am J Physiol Endocrinol Metab; 2005 Apr; 288(4):E693-700. PubMed ID: 15562254
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Vitamin D deficiency-induced muscle wasting occurs through the ubiquitin proteasome pathway and is partially corrected by calcium in male rats.
    Bhat M; Kalam R; Qadri SS; Madabushi S; Ismail A
    Endocrinology; 2013 Nov; 154(11):4018-29. PubMed ID: 23928374
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Acidosis and glucocorticoids concomitantly increase ubiquitin and proteasome subunit mRNAs in rat muscle.
    Price SR; England BK; Bailey JL; Van Vreede K; Mitch WE
    Am J Physiol; 1994 Oct; 267(4 Pt 1):C955-60. PubMed ID: 7943291
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Role of different proteolytic pathways in degradation of muscle protein from streptozotocin-diabetic rats.
    Pepato MT; Migliorini RH; Goldberg AL; Kettelhut IC
    Am J Physiol; 1996 Aug; 271(2 Pt 1):E340-7. PubMed ID: 8770029
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Differential regulation of muscle protein turnover in response to emphysema and acute pulmonary inflammation.
    Ceelen JJM; Schols AMWJ; van Hoof SJ; de Theije CC; Verhaegen F; Langen RCJ
    Respir Res; 2017 May; 18(1):75. PubMed ID: 28464882
    [TBL] [Abstract][Full Text] [Related]  

  • 78. L-Carnitine: an adequate supplement for a multi-targeted anti-wasting therapy in cancer.
    Busquets S; Serpe R; Toledo M; Betancourt A; Marmonti E; Orpí M; Pin F; Capdevila E; Madeddu C; López-Soriano FJ; Mantovani G; Macciò A; Argilés JM
    Clin Nutr; 2012 Dec; 31(6):889-95. PubMed ID: 22608917
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The lumbrical muscle: a novel in situ system to evaluate adult skeletal muscle proteolysis and anticatabolic drugs for therapeutic purposes.
    Bergantin LB; Figueiredo LB; Godinho RO
    J Appl Physiol (1985); 2011 Dec; 111(6):1710-8. PubMed ID: 21921242
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The AP-1/NF-kappaB double inhibitor SP100030 can revert muscle wasting during experimental cancer cachexia.
    Moore-Carrasco R; Busquets S; Almendro V; Palanki M; López-Soriano FJ; Argilés JM
    Int J Oncol; 2007 May; 30(5):1239-45. PubMed ID: 17390027
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.